Centessa Pharmaceuticals

CNTA

Market cap $6.13B

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company.

Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.

Centessa possesses a promising sleep medicine pipeline. The clinical-stage company's experimental therapies have blockbuster potential.

Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entered into a definitive agreement regarding its acquisition by Eli Lilly and Company (“Lilly”) on 31 March 2026 (US local time).

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.

MILWAUKEE, March 31, 2026 /PRNewswire/ -- LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash, with a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones. The acquisition adds Centessa's sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly's neuroscience business.

Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.